000136746 001__ 136746
000136746 005__ 20240229105056.0
000136746 0247_ $$2doi$$a10.1007/s00204-018-2234-8
000136746 0247_ $$2pmid$$apmid:29947893
000136746 0247_ $$2pmc$$apmc:PMC6063332
000136746 0247_ $$2ISSN$$a0003-9446
000136746 0247_ $$2ISSN$$a0340-5761
000136746 0247_ $$2ISSN$$a1432-0738
000136746 0247_ $$2altmetric$$aaltmetric:44939154
000136746 037__ $$aDKFZ-2018-01184
000136746 041__ $$aeng
000136746 082__ $$a610
000136746 1001_ $$0P:(DE-He78)556dfbcf5489cf998946e2b316deca4d$$aKolbinger, Fiona$$b0$$eFirst author
000136746 245__ $$aThe HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines.
000136746 260__ $$aBerlin$$bSpringer$$c2018
000136746 3367_ $$2DRIVER$$aarticle
000136746 3367_ $$2DataCite$$aOutput Types/Journal article
000136746 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659961557_8496
000136746 3367_ $$2BibTeX$$aARTICLE
000136746 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136746 3367_ $$00$$2EndNote$$aJournal Article
000136746 520__ $$aHigh histone deacetylase (HDAC) 8 and HDAC10 expression levels have been identified as predictors of exceptionally poor outcomes in neuroblastoma, the most common extracranial solid tumor in childhood. HDAC8 inhibition synergizes with retinoic acid treatment to induce neuroblast maturation in vitro and to inhibit neuroblastoma xenograft growth in vivo. HDAC10 inhibition increases intracellular accumulation of chemotherapeutics through interference with lysosomal homeostasis, ultimately leading to cell death in cultured neuroblastoma cells. So far, no HDAC inhibitor covering HDAC8 and HDAC10 at micromolar concentrations without inhibiting HDACs 1, 2 and 3 has been described. Here, we introduce TH34 (3-(N-benzylamino)-4-methylbenzhydroxamic acid), a novel HDAC6/8/10 inhibitor for neuroblastoma therapy. TH34 is well-tolerated by non-transformed human skin fibroblasts at concentrations up to 25 µM and modestly impairs colony growth in medulloblastoma cell lines, but specifically induces caspase-dependent programmed cell death in a concentration-dependent manner in several human neuroblastoma cell lines. In addition to the induction of DNA double-strand breaks, HDAC6/8/10 inhibition also leads to mitotic aberrations and cell-cycle arrest. Neuroblastoma cells display elevated levels of neuronal differentiation markers, mirrored by formation of neurite-like outgrowths under maintained TH34 treatment. Eventually, after long-term treatment, all neuroblastoma cells undergo cell death. The combination of TH34 with plasma-achievable concentrations of retinoic acid, a drug applied in neuroblastoma therapy, synergistically inhibits colony growth (combination index (CI) < 0.1 for 10 µM of each). In summary, our study supports using selective HDAC inhibitors as targeted antineoplastic agents and underlines the therapeutic potential of selective HDAC6/8/10 inhibition in high-grade neuroblastoma.
000136746 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000136746 588__ $$aDataset connected to CrossRef, PubMed,
000136746 7001_ $$0P:(DE-He78)700a3a9eaae170adaad6cfbd3d696f93$$aKoeneke, Emily$$b1
000136746 7001_ $$0P:(DE-He78)53112ef656923758316e7079710bc988$$aRidinger, Johannes$$b2
000136746 7001_ $$aHeimburg, Tino$$b3
000136746 7001_ $$0P:(DE-He78)ac0a5b72ef637d417bb9c7c470ca27e9$$aMüller, Michael$$b4
000136746 7001_ $$aBayer, Theresa$$b5
000136746 7001_ $$aSippl, Wolfgang$$b6
000136746 7001_ $$aJung, Manfred$$b7
000136746 7001_ $$0P:(DE-He78)c7583ac8e62bee614c7c3fc498427fac$$aGunkel, Nikolas$$b8$$udkfz
000136746 7001_ $$0P:(DE-He78)f0af962ddbc82430e947390b2f3f6e49$$aMiller, Aubry$$b9
000136746 7001_ $$0P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aWestermann, Frank$$b10
000136746 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b11
000136746 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b12$$eLast author
000136746 773__ $$0PERI:(DE-600)1458459-1$$a10.1007/s00204-018-2234-8$$gVol. 92, no. 8, p. 2649 - 2664$$n8$$p2649 - 2664$$tArchives of toxicology$$v92$$x1432-0738$$y2018
000136746 909CO $$ooai:inrepo02.dkfz.de:136746$$pVDB
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)556dfbcf5489cf998946e2b316deca4d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)700a3a9eaae170adaad6cfbd3d696f93$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)53112ef656923758316e7079710bc988$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ac0a5b72ef637d417bb9c7c470ca27e9$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c7583ac8e62bee614c7c3fc498427fac$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f0af962ddbc82430e947390b2f3f6e49$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)91f32735ee876c579d63c05a7f4778dd$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000136746 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000136746 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000136746 9141_ $$y2018
000136746 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000136746 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136746 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136746 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136746 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bARCH TOXICOL : 2015
000136746 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136746 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136746 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000136746 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000136746 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136746 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136746 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000136746 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000136746 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bARCH TOXICOL : 2015
000136746 9201_ $$0I:(DE-He78)G340-20160331$$kG340$$lKKE Pädiatrische Onkologie$$x0
000136746 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000136746 9201_ $$0I:(DE-He78)G404-20160331$$kG404$$lWirkstoffforschung$$x2
000136746 9201_ $$0I:(DE-He78)B087-20160331$$kB087$$lB087 Neuroblastom Genomik$$x3
000136746 980__ $$ajournal
000136746 980__ $$aVDB
000136746 980__ $$aI:(DE-He78)G340-20160331
000136746 980__ $$aI:(DE-He78)L101-20160331
000136746 980__ $$aI:(DE-He78)G404-20160331
000136746 980__ $$aI:(DE-He78)B087-20160331
000136746 980__ $$aUNRESTRICTED